Sight Sciences Continues To Expect Double-Digit Surgical Glaucoma Revenue Growth In H2
Sight Sciences Continues To Expect Double-Digit Surgical Glaucoma Revenue Growth In H2
Sight Sciences預計H2手術性青光眼營業收入將實現兩位數增長。
However, the Company expects Dry Eye revenue to decrease as it implements an increase in dry eye pricing effective October 1, 2024, which it believes will have a significant negative impact on cash-pay procedure volumes in the second half of 2024, before it expects a return to growth in 2025 with market access wins.
然而，公司預計隨着2024年10月1日實施乾眼症定價的提高，乾眼症的營業收入將會下降，公司認爲這將對2024年下半年現金支付手術量產生重大負面影響，預計在2025年市場準入獲得後才會恢復增長。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。